ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 9.16 Billion JPY | 8.28% |
| 2022 | 8.23 Billion JPY | 7.62% |
| 2021 | 7.68 Billion JPY | 12.78% |
| 2020 | 6.97 Billion JPY | 32.32% |
| 2019 | 5.26 Billion JPY | 19.7% |
| 2018 | 4.4 Billion JPY | -15.65% |
| 2017 | 5.21 Billion JPY | 21.51% |
| 2016 | 4.29 Billion JPY | 33.26% |
| 2015 | 3.22 Billion JPY | -0.09% |
| 2014 | 3.53 Billion JPY | 2.06% |
| 2013 | 3.43 Billion JPY | -9.19% |
| 2012 | 4.05 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.13 Billion JPY | -12.07% |
| 2024 Q1 | 2.42 Billion JPY | 79.39% |
| 2023 FY | - JPY | 8.28% |
| 2023 Q1 | 1.82 Billion JPY | 3468.63% |
| 2023 Q2 | 1.29 Billion JPY | -28.74% |
| 2023 Q3 | 2.54 Billion JPY | 96.22% |
| 2023 Q4 | 1.54 Billion JPY | -39.29% |
| 2022 Q4 | 51 Million JPY | -97.76% |
| 2022 FY | - JPY | 7.62% |
| 2022 Q3 | 2.27 Billion JPY | 85.32% |
| 2022 Q2 | 1.22 Billion JPY | -32.56% |
| 2022 Q1 | 1.81 Billion JPY | 1145.21% |
| 2021 Q3 | 2.06 Billion JPY | 137.78% |
| 2021 FY | - JPY | 12.78% |
| 2021 Q4 | 146 Million JPY | -92.91% |
| 2021 Q2 | -5.45 Billion JPY | -506.03% |
| 2021 Q1 | 1.34 Billion JPY | 107.89% |
| 2020 Q3 | 2.77 Billion JPY | 42.44% |
| 2020 FY | - JPY | 32.32% |
| 2020 Q1 | 1.83 Billion JPY | 98.36% |
| 2020 Q2 | 1.94 Billion JPY | 5.78% |
| 2020 Q4 | 646 Million JPY | -76.69% |
| 2019 Q2 | 802 Million JPY | -46.3% |
| 2019 Q3 | 1.42 Billion JPY | 78.12% |
| 2019 Q4 | 927.25 Million JPY | -35.09% |
| 2019 Q1 | 1.49 Billion JPY | 1155.48% |
| 2019 FY | - JPY | 19.7% |
| 2018 FY | - JPY | -15.65% |
| 2018 Q4 | -141.5 Million JPY | -106.38% |
| 2018 Q3 | 2.21 Billion JPY | 589.74% |
| 2018 Q2 | 321.5 Million JPY | -82.31% |
| 2018 Q1 | 1.81 Billion JPY | 5079.45% |
| 2017 FY | - JPY | 21.51% |
| 2017 Q2 | 1.36 Billion JPY | -19.64% |
| 2017 Q3 | 2.21 Billion JPY | 61.64% |
| 2017 Q4 | -36.5 Million JPY | -101.65% |
| 2017 Q1 | 1.7 Billion JPY | 284.91% |
| 2016 FY | - JPY | 33.26% |
| 2016 Q1 | 977.25 Million JPY | 680.24% |
| 2016 Q2 | 1.45 Billion JPY | 49.19% |
| 2016 Q3 | 1.15 Billion JPY | -20.63% |
| 2016 Q4 | 442.25 Million JPY | -61.78% |
| 2015 Q4 | 125.25 Million JPY | -91.67% |
| 2015 Q3 | 1.5 Billion JPY | 131.73% |
| 2015 Q2 | 648.5 Million JPY | -5.71% |
| 2015 Q1 | 687.75 Million JPY | 2534.51% |
| 2015 FY | - JPY | -0.09% |
| 2014 Q3 | 1.43 Billion JPY | 23.82% |
| 2014 Q1 | 960.75 Million JPY | 355.35% |
| 2014 FY | - JPY | 2.06% |
| 2014 Q4 | -28.25 Million JPY | -101.97% |
| 2014 Q2 | 1.15 Billion JPY | 20.69% |
| 2013 Q3 | 1.58 Billion JPY | 227.73% |
| 2013 Q1 | 1.39 Billion JPY | 628.2% |
| 2013 Q2 | 485 Million JPY | -65.22% |
| 2013 FY | - JPY | -9.19% |
| 2013 Q4 | -376.25 Million JPY | -123.67% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q4 | 191.5 Million JPY | -87.4% |
| 2012 Q2 | 630.5 Million JPY | 0.0% |
| 2012 Q3 | 1.51 Billion JPY | 141.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -52.184% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 98.952% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 103.26% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 95.092% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -1504.807% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 74.751% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 25.304% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 91.113% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -608.662% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 50.038% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | -2.117% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -149.673% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -553.1% |
| Tsumura & Co. | 30.77 Billion JPY | 70.223% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 51.052% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -73.838% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 74.215% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -33.144% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 47.705% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 11.004% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 344.347% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | -21.316% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 1383.333% |
| MedRx Co., Ltd | -884.51 Million JPY | 1135.934% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -65.508% |
| Solasia Pharma K.K. | -635 Million JPY | 1542.992% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 485.986% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 75.15% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1802.245% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 64.546% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -79.609% |